KMID : 1011320230150010001
|
|
Journal of Pharmacoepidemiology and Risk Management 2023 Volume.15 No. 1 p.1 ~ p.10
|
|
Hypersensitivity Reactions to Anticancer Monoclonal Antibodies
|
|
Choi Bo-Yoon
Jang Ha-Young Kang Hye-Ryun Oh Jung-Mi
|
|
Abstract
|
|
|
Therapeutic monoclonal antibodies (TmAbs) are new treatment options for cancer. While their use is more common, hypersensitivity reactions (HSRs) to these drugs have been increased, preventing the use of first-line therapies. The aim of this review is to update and discuss the HSRs to TmAbs in their clinical features and management. Type 1 hypersensitivity is the most common type of the HSRs to TmAbs, followed by cytokine release reactions (CRRs) and type 4 hypersensitivity. Mixed reactions of various types might also occur. TmAbs can have different immunogenicity depending on their non-human epitope contents, target proteins, and solubilizing additives. It may be also affected by the patient¡¯s baseline condition and the number of administrations. When HSRs occur, it is recommended to classify the mechanism into type 1/type 4 hypersensitivity and CRRs. A skin test and desensitization are generally the most useful management for type 1 hypersensitivity but there is no standardized protocol for TmAbs yet. Readministration is contraindicated in type 4 hypersensitivity reactions and supportive care is effective in CCRs. Understanding the characteristics and measures for each HSRs may be helpful to ensure the safe use of anticancer monoclonal antibodies.
|
|
KEYWORD
|
|
Monoclonal antibodies, Antineoplastic agents, Hypersensitivity, Skin test, Desensitization
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|